Health Trials

the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)

1

Review clinical trials related to the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).

Participants needed: 3
Trial details
Phase: Phase 1Age: 30-75Biological sex: AllType: InterventionalSponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Updated: Jun 1, 2026
Eligibility criteria

Male or female, aged 30 to 75; [+3]

Patients diagnosed with primary Parkinson's disease, Lewy body dementia, progres... [+14]

Read more